Literature DB >> 11229648

Three dimensional conformal radiotherapy in patients with T2a-b, N0, M0 prostatic carcinoma.

C Kurtman1, B Celebioğlu, O Göğüş, M N Andrieu.   

Abstract

The current study was undertaken to evaluate the Prostate Specific Antigen (PSA) relapse free survival and the prognostic factors in a total of 38 patients with stages of T2a-b, N0, M0 prostate carcinoma treated with three-dimensional conformal radiotherapy (3D-CRT). Mean 69.63 Gy was given with 3D-CRT, the mean follow up time was 13.89 months, and the mean prebiopsied PSA level was 25.12 ng/ml. The 2-year PSA relapse free survival was 47.37% for the entire group. The 2-year PSA relapse free survival rates were 100% and 44.74% for the patients with Gleason score < or = 7 and greater than 7 (p < or = 0.05). Patients with prebiopsied PSA level < or = 10 ng/ml and the stages of T2a or T2b did not show any significant differences (p > or = 0.05). Although the few case number and short term follow up, in this study 3D-CRT was a new effective technique to prostate cancer for our institutes and the Gleason score was important predictor of PSA relapse free survival.

Entities:  

Mesh：

Year:  2000        PMID： 11229648     DOI： 10.1023/a:1007174213087

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  20 in total

1.  Results of 3D conformal radiotherapy in the treatment of localized prostate cancer.

Authors:  N Fukunaga-Johnson; H M Sandler; P W McLaughlin; M S Strawderman; K H Grijalva; K E Kish; A S Lichter
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-05-01       Impact factor: 7.038

2.  The effect of treatment positioning on normal tissue dose in patients with prostate cancer treated with three-dimensional conformal radiotherapy.

Authors:  M J Zelefsky; L Happersett; S A Leibel; C M Burman; L Schwartz; A P Dicker; G J Kutcher; Z Fuks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-01-01       Impact factor: 7.038

3.  Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma.

Authors:  M J Zelefsky; D Cowen; Z Fuks; M Shike; C Burman; A Jackson; E S Venkatramen; S A Leibel
Journal:  Cancer       Date:  1999-06-01       Impact factor: 6.860

4.  Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer.

Authors:  J Laverdière; J L Gomez; L Cusan; E R Suburu; P Diamond; M Lemay; B Candas; A Fortin; F Labrie
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-01-15       Impact factor: 7.038

5.  Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > or = 10 NG/ML.

Authors:  G E Hanks; W R Lee; A L Hanlon; M Hunt; E Kaplan; B E Epstein; B Movsas; T E Schultheiss
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-07-15       Impact factor: 7.038

6.  Factors influencing outcome of definitive radiotherapy for localized carcinoma of the prostate.

Authors:  C A Perez; D Garcia; J R Simpson; F Zivnuska; M A Lockett
Journal:  Radiother Oncol       Date:  1989-09       Impact factor: 6.280

7.  Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose.

Authors:  W G Smit; P A Helle; W L van Putten; A J Wijnmaalen; J J Seldenrath; B H van der Werf-Messing
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-01       Impact factor: 7.038

8.  Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate.

Authors:  C Burman; C S Chui; G Kutcher; S Leibel; M Zelefsky; T LoSasso; S Spirou; Q Wu; J Yang; J Stein; R Mohan; Z Fuks; C C Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-11-01       Impact factor: 7.038

9.  Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy.

Authors:  M J Zelefsky; O Lyass; Z Fuks; T Wolfe; C Burman; C C Ling; S A Leibel
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544

10.  Locally advanced prostatic cancer: long-term toxicity outcome after three-dimensional conformal radiation therapy--a dose-escalation study.

Authors:  M J Zelefsky; Z Fuks; T Wolfe; G J Kutcher; C Burman; C C Ling; E S Venkatraman; S A Leibel
Journal:  Radiology       Date:  1998-10       Impact factor: 11.105
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.